Truist Financial Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Genmab A/S (NASDAQ:GMAB - Get Free Report) had its price objective lifted by analysts at Truist Financial from $45.00 to $46.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Truist Financial's target price would indicate a potential upside of 110.43% from the stock's current price.

GMAB has been the subject of a number of other reports. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Wall Street Zen downgraded shares of Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.80.

Genmab A/S Stock Up 1.3%

Shares of NASDAQ:GMAB traded up $0.28 during midday trading on Tuesday, hitting $21.86. 1,049,321 shares of the stock traded hands, compared to its average volume of 1,243,369. The stock has a market capitalization of $14.02 billion, a PE ratio of 12.42, a P/E/G ratio of 6.73 and a beta of 0.94. The business's 50 day moving average is $21.02 and its two-hundred day moving average is $20.73. Genmab A/S has a one year low of $17.24 and a one year high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. As a group, sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares during the last quarter. Barclays PLC lifted its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Genmab A/S during the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.